{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:38:11Z","timestamp":1790746691291,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Postgraduate Innovation Research and Practice Program of Anhui Medical University","award":["YJS20230032"],"award-info":[{"award-number":["YJS20230032"]}]},{"name":"Clinical Research Incubation Program of The Second Hospital of Anhui Medical University","award":["2020LCZD01"],"award-info":[{"award-number":["2020LCZD01"]}]},{"name":"Incubation Program of National Natural Science Foundation of China of The Second Hospital of Anhui Medical University","award":["2020GMFY04"],"award-info":[{"award-number":["2020GMFY04"]}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["2008085MH244"],"award-info":[{"award-number":["2008085MH244"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To determine the effects of roxadustat on calcification when treating renal anemia in end-stage kidney disease (ESKD) patients. A prospective cohort study enrolled participants with ESKD that either received roxadustat or no roxadustat treatment. The primary outcome was the change in the degree of hydroxyapatite (HAP) crystals deposition. The secondary outcome was calcification propensity, a measure of calcification, allowing an evaluation of the conversion process from primary to secondary calciprotein particles. A total of 205 patients were enrolled, and 187 (91.2%) completed follow-up for inclusion in the analysis and were divided into the roxadustat group (n\u2009=\u200992) and the control group (n\u2009=\u200995) based on whether or not they were taking roxadustat regularly over a 6-mo period. After roxadustat administration for 6\u00a0mo, patients exhibited increases in total RBC counts, hematocrit, hemoglobin, calcium, total ferritin binding, intact fibroblast growth factor 23 (iFGF23), secreted phosphoprotein 24 (SPP24), and calcification propensity relative to pre-treatment levels. No significant differences were observed in patients who were not treated with roxadustat. The deposition degree of HAP crystals increased by 5% and 0.01% following treatment with roxadustat in the roxadustat group and control group, respectively. Linear regression analysis found that the use of roxadustat was an independent risk factor for calcification propensity and changes in the degree of HAP crystals deposition. Roxadustat treatment may increase iFGF23, SPP24, and calcification propensity in patients with ESKD when treating these patients for renal anemia. Therefore, the clinicians should aware of this risk when treating patients with prolyl hydroxylase domain inhibitors.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf032","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:10:58Z","timestamp":1741122658000},"page":"492-499","source":"Crossref","is-referenced-by-count":4,"title":["Roxadustat increases markers of calcification in patients with end-stage kidney disease: prospective cohort study"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4799-3241","authenticated-orcid":false,"given":"Yu-yu","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University , Hefei, Anhui 230032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-feng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University , Hefei, Anhui 230032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-wen","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University , Hefei, Anhui 230032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-man","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University , Hefei, Anhui 230032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University , Hefei, Anhui 230032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9964-2078","authenticated-orcid":false,"given":"Xun-liang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University , Hefei, Anhui 230032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-juan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University , Hefei, Anhui 230032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-guang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University , Hefei, Anhui 230032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"18","key":"2025042106115384700_ref1","doi-asserted-by":"crossref","first-page":"18238","DOI":"10.18632\/aging.103681","article-title":"The mitochondrial-targeted peptide SBT-20 ameliorates inflammation and oxidative stress in chronic renal failure","volume":"12","author":"Sun","year":"2020","journal-title":"Aging"},{"issue":"3","key":"2025042106115384700_ref2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00109-021-02037-7","article-title":"Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches","volume":"99","author":"D\u00fcsing","year":"2021","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"2025042106115384700_ref3","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.kint.2016.05.020","article-title":"Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification","volume":"90","author":"Mokas","year":"2016","journal-title":"Kidney Int"},{"key":"2025042106115384700_ref4","doi-asserted-by":"crossref","first-page":"174583","DOI":"10.1016\/j.ejphar.2021.174583","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: advantages and disadvantages","volume":"912","author":"Mima","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"2025042106115384700_ref5","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2019.01584","article-title":"Zinc inhibits HIF-prolyl hydroxylase inhibitor-aggravated VSMC calcification induced by high phosphate","volume":"10","author":"Nagy","year":"2020","journal-title":"Front Physiol"},{"issue":"6","key":"2025042106115384700_ref6","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/ATVBAHA.119.312509","article-title":"Hypoxia triggers osteochondrogenic differentiation of vascular smooth muscle cells in an HIF-1 (hypoxia-inducible factor 1)-dependent and reactive oxygen species\u2013dependent manner","volume":"39","author":"Balogh","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025042106115384700_ref7","doi-asserted-by":"crossref","first-page":"119330","DOI":"10.1016\/j.carbpol.2022.119330","article-title":"Bone-like hydroxyapatite anchored on alginate microspheres for bone regeneration","volume":"287","author":"Xu","year":"2022","journal-title":"Carbohydr Polym"},{"key":"2025042106115384700_ref8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijcard.2020.08.024","article-title":"Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy","volume":"322","author":"Schiffer","year":"2021","journal-title":"Int J Cardiol"},{"issue":"3","key":"2025042106115384700_ref9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00223-020-00783-3","article-title":"Secreted phosphoprotein 24 is a biomarker of mineral metabolism","volume":"108","author":"Turner","year":"2021","journal-title":"Calcified Tissue Int"},{"issue":"1","key":"2025042106115384700_ref10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-022-01036-1","article-title":"Calciprotein particle synthesis strategy determines in vitro calcification potential","volume":"112","author":"Zeper","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"2025042106115384700_ref11","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/ATVBAHA.120.314187","article-title":"Serum calcification propensity and the risk of cardiovascular and all-cause mortality in the general population: the PREVEND study","volume":"40","author":"Eelderink","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2025042106115384700_ref12","doi-asserted-by":"crossref","first-page":"17578","DOI":"10.1038\/s41598-020-74592-x","article-title":"A novel assay to measure calcification propensity: from laboratory to humans","volume":"10","author":"Perez","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"2025042106115384700_ref13","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1038\/s41598-017-07203-x","article-title":"A novel pharmacodynamic assay to evaluate the effects of crystallization inhibitors on calcium phosphate crystallization in human plasma","volume":"7","author":"Ferrer","year":"2017","journal-title":"Sci Rep"},{"issue":"9","key":"2025042106115384700_ref14","doi-asserted-by":"crossref","first-page":"e52709","DOI":"10.7554\/eLife.52709","article-title":"High-phytate\/low-calcium diet is a risk factor for crystal nephropathies, renal phosphate wasting, and bone loss","volume":"9","author":"Kim","year":"2020","journal-title":"eLife"},{"key":"2025042106115384700_ref15","doi-asserted-by":"crossref","first-page":"773208","DOI":"10.3389\/fnins.2021.773208","article-title":"Kernelized k-local hyperplane distance nearest-neighbor model for predicting cerebrovascular disease in patients with end-stage renal disease","volume":"15","author":"Liu","year":"2021","journal-title":"Front Neurosci"},{"issue":"9","key":"2025042106115384700_ref16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/biomedicines8090337","article-title":"Association between serum zinc and calcification propensity (T50) in patients with type 2 diabetes mellitus and in vitro effect of exogenous zinc on T50","volume":"8","author":"Nakatani","year":"2020","journal-title":"Biomedicines"},{"issue":"1","key":"2025042106115384700_ref17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"Epstein","year":"2001","journal-title":"Cell"},{"issue":"5545","key":"2025042106115384700_ref18","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.1066373","article-title":"A conserved family of prolyl-4-hydroxylases that modify HIF","volume":"294","author":"Bruick","year":"2001","journal-title":"Science"},{"issue":"10","key":"2025042106115384700_ref19","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1164\/rccm.201512-2380OC","article-title":"Role for runt-related transcription factor 2 in proliferative and calcified vascular lesions in pulmonary arterial hypertension","volume":"194","author":"Ruffenach","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2025042106115384700_ref20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-002016","article-title":"Serum calcification propensity is associated with HbA1c in type 2 diabetes mellitus","volume":"9","author":"Mencke","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"2025042106115384700_ref21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2215\/CJN.05080422","article-title":"Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study","volume":"18","author":"Donovan","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2025042106115384700_ref22","doi-asserted-by":"crossref","first-page":"107556","DOI":"10.1016\/j.jsb.2020.107556","article-title":"Alterations of bone material properties in adult patients with X-linked hypophosphatemia (XLH)","volume":"211","author":"Fratzl-Zelman","year":"2020","journal-title":"J Struct Biol"},{"issue":"4","key":"2025042106115384700_ref23","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.kint.2019.10.019","article-title":"Calciprotein particles regulate fibroblast growth factor-23 expression in osteoblasts","volume":"97","author":"Akiyama","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"2025042106115384700_ref24","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/ki.2013.332","article-title":"Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency","volume":"85","author":"Jimbo","year":"2014","journal-title":"Kidney Int"},{"issue":"12","key":"2025042106115384700_ref25","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1007\/s12011-021-02598-1","article-title":"The effect of iron supplementation on FGF23 in chronic kidney disease patients: a systematic review and time-response meta-analysis","volume":"199","author":"Abu-Zaid","year":"2021","journal-title":"Biol Trace Elem Res"},{"issue":"6","key":"2025042106115384700_ref26","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/hae.14623","article-title":"FGF23 and SOX9 expression in haemophilic cartilage: in vitro studies of the effects of iron","volume":"28","author":"Zheng","year":"2022","journal-title":"Haemophilia"},{"issue":"11","key":"2025042106115384700_ref27","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14434","article-title":"Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)","volume":"8","author":"Noonan","year":"2020","journal-title":"Physiol Rep"},{"issue":"3","key":"2025042106115384700_ref28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/ckj\/sfaa042","article-title":"Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis","volume":"14","author":"Honda","year":"2021","journal-title":"Clin Kidney J"},{"issue":"3","key":"2025042106115384700_ref29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/bcp.15055","article-title":"Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: a systematic review and meta-analysis","volume":"88","author":"Zheng","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2025042106115384700_ref30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.kint.2021.03.019","article-title":"Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone","volume":"100","author":"Hanudel","year":"2021","journal-title":"Kidney Int"},{"issue":"9","key":"2025042106115384700_ref31","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2025042106115384700_ref32","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J Am Soc Nephrol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf032\/62196869\/zjaf032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/4\/492\/62196869\/zjaf032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/4\/492\/62196869\/zjaf032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T10:12:13Z","timestamp":1745230333000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/40\/4\/492\/8045196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,27]]},"published-print":{"date-parts":[[2025,4,21]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf032","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,2,27]]}}}